Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gw842166X. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 known ✓ | P34972 | 20/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.84 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.84 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.75 |
| ▸ | CNR1 | P21554 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gw842166X SCHEMBL29509992 | 1.00 | CNR2 (1.00) | CNR2CYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3380666 | 0.94 | CNR2 (0.88) | CNR2CYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL13503317 | 0.93 | CNR2 (1.00) | CNR2CYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL13503338 | 0.92 | CNR2 (1.00) | CNR2CYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL13069718 | 0.92 | CNR2 (1.00) | CNR2CYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL13503339 | 0.92 | CNR2 (0.85) | CNR2CYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL13503387 | 0.92 | CNR2 (0.85) | CNR2CYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3380966 | 0.92 | CNR2 (0.85) | CNR2CYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3378716 | 0.92 | CNR2 (0.85) | CNR2CYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL13503343 | 0.91 | CNR2 (0.84) | CNR2CYP2C9CYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739302-A2 | HYALURONIC ACID BASED DRUG DELIVERY SYSTEMS | Cella Therapeutics, LLC (US) | 2026-05-13 | — | — | EP | claimed |
| US-20260102502-A1 | CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY | UNIV JOHNS HOPKINS (US) | 2026-04-16 | — | — | US | claimed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4577247-A1 | CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY | The Johns Hopkins University (US) | 2025-07-02 | — | — | EP | claimed |
| WO-2025010288-A2 | HYALURONIC ACID BASED DRUG DELIVERY SYSTEMS | VISUS THERAPEUTICS, INC. (US) | 2025-01-09 | — | — | WO | claimed |
| CN-118620835-A | Method for culturing human decidua mesenchymal stem cells and culture kit | 深圳市中佳生物医疗科技有限公司 | 2024-09-10 | — | — | CN | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2024044776-A1 | CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-02-29 | — | — | WO | claimed |
| EP-4321614-A1 | METHOD FOR PREPARING OLIGODENDROCYTES AND USE | Shenzhen Exoneuglia Biomedical Technology Co., Ltd. (CN) | 2024-02-14 | — | — | EP | claimed |
| WO-2023165062-A1 | METHOD FOR PREPARING OLIGODENDROCYTES AND USE | 深圳市夏同生物医药科技有限公司 | 2023-09-07 | — | — | WO | claimed |
| CN-114262686-A | Preparation method and application of oligodendrocyte | 深圳市夏同生物医药科技有限公司 | 2022-04-01 | — | — | CN | claimed |
| US-20170014355-A1 | CANNABINOID RECEPTOR TREATMENTS | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2017-01-19 | — | — | US | claimed |
| WO-2013025984-A2 | CANNABINOID RECEPTOR TREATMENTS | TEMPLE UNIVERSITY (US) | 2013-02-21 | — | — | WO | claimed |
| US-12636251-B1 | Glycoside-containing aqueous formulations having a lipophilic active component | Doane Technology Group LLC (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260131008-A1 | HYALURONIC ACID BASED DRUG DELIVERY SYSTEMS | CELLA THERAPEUTICS LLC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4739302-A2 | HYALURONIC ACID BASED DRUG DELIVERY SYSTEMS | Cella Therapeutics, LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20080234259-A1 | Novel Cannabinoid Receptor Ligands, Pharmaceutical Compositions Containing Them, and Process For Their Preparation | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-09-25 | — | — | US | disclosed |
| EP-1878725-A2 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LIMITED (GB) | 2008-01-16 | — | — | EP | disclosed |
| WO-2007026215-A1 | PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING? THEM, AND PROCESSES FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS S.A. (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170014355-A1 | CANNABINOID RECEPTOR TREATMENTS | CNR1, CNR2, GPR18 | CNR2 2/4885CYP2C9 786/4885CYP1A2 1041/4885 |
| US-20260131008-A1 | HYALURONIC ACID BASED DRUG DELIVERY SYSTEMS | SLC26A6, SLC26A3, SLC9A2 | CNR2 1399/4885CYP2C9 1989/4885CYP1A2 2989/4885 |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | CNR2 204/4885CYP2C9 313/4885CYP1A2 871/4885 |
| US-20260102502-A1 | CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY | CNR1, CNR2, GPR18 | CNR2 2/4885CYP2C9 495/4885CYP1A2 1042/4885 |
| US-12636251-B1 | Glycoside-containing aqueous formulations having a lipophilic active component | CNR2, CNR1, LIPC | CNR2 1/4885CYP2C9 2093/4885CYP1A2 1304/4885 |
| US-20080234259-A1 | Novel Cannabinoid Receptor Ligands, Pharmaceutical Compositions Containing Them, and Process For Their Preparation | CNR2, CNR1, OPRL1 | CNR2 1/4885CYP2C9 2910/4885CYP1A2 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.